Gliotherapy

Gliotherapy is a French biotechnology company dedicated to developing innovative treatments for glioblastoma multiforme, one of the most aggressive forms of brain cancer. The company's approach focuses on targeting specific G protein-coupled receptors (GPCRs) that are overexpressed in glioma cells to inhibit tumor growth and recurrence. By leveraging a unique pharmacological strategy, Gliotherapy aims to overcome the limitations of current standard-of-care therapies, such as temozolomide and radiotherapy. The company is currently advancing its lead candidates through pre-clinical development with the goal of providing more effective options for patients with high-grade gliomas.